I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience Alzheimer's Disease

Alzheimer's Disease

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Apr 5 / Roche and Genentech
Impact of ARIA on cerbral volume changes with gantenerumab
Our study indicated that while ARIA did not significantly impact whole cortex or white matter volume loss, it was associated with greater ventricular expansion but reduced external cerebrospinal fluid (CSF) expansion compared to treated participants without ARIA, suggesting a redistribution of CSF due to ARIA. Notably, this ventricular enlargement was not linked to worsening clinical or cognitive outcomes.
Neuroscience Alzheimer Disease ADPD-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 3 / Roche and Genentech
Trontinemab - from early preclinical groundwork to the clinical validation of the Brainshuttle TM Platform
The development of trontinemab started more than 10 years ago, when the Roche team began the development of the Brainshuttle TM technology. Today, trontinemab is the most advanced Brainshutle TM -based molecule in clinical development. The latest results on amyloid reduction and safety are included this presentation. Results are consistent to those previously reported, now with a larger set of results from the full Cohort 3 and Cohort 4 Part 1 results, and full Cohort 3 and 1/3 of Cohort 4 Part 2 results.
Neuroscience Alzheimer Disease ADPD-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 3 / Roche and Genentech
Interim biomarker results of trontinemab, a novel Brainshuttle TM antibody in development for the treatment of Alzheimer's disease
In addition to changes in amyloid PET, new results on relevant CSF and plasma downstream biomarkers showing a trend in the right direction and volumetric MRI results in line with the recent literature.
Neuroscience Alzheimer Disease ADPD-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 3 / Roche and Genentech
Discovery of blood-based biomarkers for the detection and monitoring of amyloid related imaging abnormalities (ARIA)
Our analysis was one of the largest to date investigating blood-based biomarkers that could be used for the detection or monitoring of ARIA.
Neuroscience Alzheimer Disease ADPD-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 1 / Roche
Evaluating future IVD plasma p-Tau181 and ApoE4 immunoassays for rule out of amyloid pathology in a multi-center study reflective of routine clinical practice
This presentation showcases the results of the cut off determination study arm for validation of plasma pTau181 and ApoE4, in a population reflective of routine clinical practice.
Neuroscience Alzheimer Disease ADPD-2025

Sign up or login to unlock the full suite of MEDICALLY features
Oct 31 / Roche
Concordance between the updated Elecsys CSF immunoassays and amyloid PET for the diagnosis of Alzheimer’s disease: findings from the Apollo study
The aim of this study was to assess the concordance between amyloid status classification based on the Elecsys Abeta42 and its ratios with pTau and tTau, and the visual evaluation of amyloid positron electromagnetic tomography (PET) scans.
Neuroscience Alzheimer Disease CTAD-2024
Treatment management Research advancements
  • Alzheimer Disease
0 results
Upcoming congresses
Access to Roche and Genentech's medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.